Comparable daughter radionuclide redistribution with superior tumor absorbed dose of the SSTR2 antagonist Ac-DOTA-TATE

This study demonstrates that the SSTR2 antagonist [225Ac]Ac-SSO110 achieves superior tumor absorbed dose and retention compared to the internalizing agonist [225Ac]Ac-DOTA-TATE without increased redistribution of daughter radionuclides, challenging the hypothesis that cellular internalization is required for effective daughter retention in targeted alpha therapy.

The Gist

The Big Picture: A High-Powered Cancer Treatment

Imagine you have a very dangerous cancer cell that needs to be destroyed. Scientists have developed a "smart bomb" treatment called Targeted Alpha Therapy.

• The Bomb: The bomb is a radioactive atom called Actinium-225. It's incredibly powerful. When it explodes (decays), it doesn't just release one blast; it releases a chain reaction of four massive "alpha particle" explosions. These blasts are so strong they can shred the DNA of cancer cells, killing them instantly.
• The Delivery Truck: To get this bomb to the cancer and not the healthy body, it's strapped to a "delivery truck" (a molecule) that knows exactly where the cancer is. In this study, they compared two types of trucks:
  1. The Agonist Truck (DOTA-TATE): This truck drives up to the cancer, knocks on the door, gets invited inside the house (the cell), and locks the door behind it.
  2. The Antagonist Truck (SSO110): This truck drives up to the cancer, knocks on the door, but doesn't go inside. It just sits right on the doorstep, holding the bomb tight.

The Big Fear: The "Recoil" Problem

Here is the tricky part. When the Actinium-225 bomb explodes, it creates a tiny, violent kickback (called recoil). It's like a cannon firing a shell; the cannon jumps backward.

Scientists were worried that this kickback would knock the "daughter" radioactive atoms (the next bombs in the chain) off the delivery truck.

• The Old Theory: They thought the Agonist Truck (the one that goes inside the house) was safer. The idea was: "If the truck is inside the house, even if the bomb kicks the daughter atoms off, they are trapped inside the house and can't escape to hurt the neighborhood."
• The Fear: They thought the Antagonist Truck (sitting on the doorstep) was dangerous. If the bomb kicks the daughter atoms off while the truck is outside, those radioactive atoms might fly away into the bloodstream and hurt healthy organs like the kidneys or liver.

What the Study Did

The researchers set up a race between these two trucks in mice with lung cancer. They wanted to see:

1. Which truck delivered more bombs to the tumor?
2. Did the "kickback" cause the radioactive atoms to fly away from the doorstep truck more than from the inside-the-house truck?
3. Did the healthy organs get hurt by stray radioactive atoms?

The Surprising Results

The results completely flipped the old theory on its head.

1. The Doorstep Truck Won the Race
The Antagonist Truck (SSO110) was actually much better at the job.

• It stuck to the cancer cells longer.
• It carried more bombs to the tumor.
• It delivered 2.8 times more radiation dose to the tumor than the Agonist truck.
• It was also much better at avoiding the kidneys (the main organ at risk), meaning it was safer for the body overall.

2. The "Kickback" Didn't Matter
The big fear was that the Antagonist Truck would lose its radioactive "daughters" because it wasn't inside the cell.

• The Reality: Almost none of the radioactive atoms escaped. Whether the truck was inside the house or on the doorstep, the radioactive atoms stayed put.
• The Analogy: Imagine the cancer cell is a sticky trap. Even if the truck isn't inside, the "sticky" surface of the cell is so strong that when the bomb kicks the daughter atoms off, they don't fly away. They just land on the cell surface and stay there, still blasting the cancer.
• The Math: The amount of radiation lost from the tumor was tiny (less than 5%) for both trucks. It didn't matter which one you used; the cancer got the full dose.

3. Healthy Organs Were Safe
The researchers checked the blood, kidneys, and liver to see if any radioactive atoms had escaped and were floating around.

• Result: Nothing significant was found. The trucks cleared out of the blood very quickly, and the radioactive atoms didn't hang around in healthy organs.

The Takeaway

For a long time, scientists thought, "To keep the radioactive bombs safe inside the tumor, the delivery truck must go inside the cell."

This paper says: "Actually, that's not true."

You don't need the truck to go inside the house to keep the bombs safe. A high-quality truck that just sits on the doorstep (the Antagonist) works even better. It delivers more firepower to the cancer, keeps the radioactive debris contained, and is safer for the patient.

In short: The "Antagonist" approach is a superior way to deliver this powerful cancer-killing treatment, and we don't need to worry about the radioactive atoms flying away just because the truck stays outside the cell.

Technical Summary

1. Problem Statement

Targeted Alpha Therapy (TAT) using Actinium-225 ($^{225}$Ac) is a promising modality for treating neuroendocrine tumors due to its high linear energy transfer (LET) and ability to cause double-strand DNA breaks. However, a critical challenge in $^{225}$Ac therapy is the recoil effect during alpha decay. The recoil energy (~100–200 keV) is sufficient to break the chemical bonds holding the radionuclide to the chelator, releasing daughter radionuclides (specifically $^{213}$Bi, $t_{1/2}=46$ min) from the targeting vector.

The Prevailing Hypothesis: It has been widely assumed that receptor-mediated internalization is required to retain these daughter radionuclides within the tumor cell. Under this paradigm, internalizing agonists (like DOTA-TATE) are expected to trap daughters effectively, while non-internalizing antagonists (like SSO110) would allow daughters to escape, leading to:

• Reduced Tumor Absorbed Dose (TAD).
• Increased off-target radiation exposure (to kidneys, bone marrow, etc.).

The Knowledge Gap: There is a lack of direct, quantitative experimental evidence comparing daughter redistribution between internalizing agonists and non-internalizing antagonists in $^{225}$Ac-labeled radiopharmaceuticals.

2. Methodology

The study performed a head-to-head comparison between the non-internalizing SSTR2 antagonist [225Ac]Ac-SSO110 and the internalizing agonist [225Ac]Ac-DOTA-TATE.

• In Vivo Model: Balb/c nude mice bearing NCI-H69 small cell lung cancer xenografts (chosen for moderate/heterogeneous SSTR2 expression).
• Biodistribution & Dosimetry:
  • Mice received a single IV injection (90 kBq) of either conjugate.
  • Organs (tumor, blood, bone marrow, kidneys, liver, intestines) were harvested up to 96 hours post-injection.
  • Quantification: Gamma counting was used to measure $^{213}$Bi activity (400–480 keV window). Counts were recorded every 13 minutes for 20 hours to fit bi-exponential models, distinguishing between $^{213}$Bi in secular equilibrium with $^{225}$Ac and free/redistributed $^{213}$Bi.
  • TAD Calculation: Tumor Absorbed Dose was calculated using MIRD formalism under two scenarios: (1) assuming no daughter redistribution, and (2) correcting for experimentally derived $^{213}$Bi loss.
• In Vitro Binding Studies:
  • Saturation Binding: Determined equilibrium dissociation constants ($K_D$) for both $^{225}$Ac- and $^{177}$Lu-labeled SSO110 on AR42J cells.
  • Real-Time Binding: Used LigandTracer® White to monitor association and dissociation kinetics of $^{225}$Ac-SSO110 in real-time, specifically looking for sustained cell-associated beta signals indicating retention.

3. Key Contributions

• Direct Quantitative Comparison: This is one of the first studies to directly quantify and compare $^{213}$Bi redistribution kinetics between an internalizing agonist and a non-internalizing antagonist using $^{225}$Ac.
• Dosimetric Correction: The study provides experimentally derived correction factors for TAD calculations, moving beyond theoretical assumptions about daughter retention.
• Mechanistic Insight: It challenges the dogma that internalization is a prerequisite for effective daughter retention in peptide-based TAT, proposing that pharmacokinetics and receptor affinity are more dominant factors.

4. Key Results

A. Biodistribution and Tumor Uptake

• Tumor Retention: [225Ac]Ac-SSO110 demonstrated higher tumor uptake and prolonged retention compared to [225Ac]Ac-DOTA-TATE.
  • Peak uptake for SSO110: 6.8% IA/g at 4h.
  • Peak uptake for DOTA-TATE: 5.0% IA/g at 0.5h (declined rapidly).
• Tumor-to-Kidney Ratio: SSO110 achieved a 1.9-fold higher tumor-to-kidney ratio at 96 hours compared to DOTA-TATE.
• Clearance: Both compounds cleared rapidly from the blood (below detection by 48h).

B. Daughter Radionuclide Redistribution ($^{213}$Bi)

• Tumor Loss: Contrary to the hypothesis, the loss of $^{213}$Bi from the tumor was minimal and comparable between both agents.
  • Max loss for SSO110: 3.5% (at 0.5h).
  • Max loss for DOTA-TATE: 2.0% (at 0.5h).
  • Loss dropped below 1% after 24 hours for both.
• Off-Target Accumulation: No sustained accumulation of $^{213}$Bi was observed in blood, kidneys, or liver. Only minimal, transient activity was detected in bone marrow and intestines.
• Dosimetric Impact: Accounting for $^{213}$Bi redistribution reduced the calculated TAD by less than 5% for both agents.

C. Therapeutic Efficacy (TAD)

• Despite the lack of internalization, [225Ac]Ac-SSO110 delivered a 2.8-fold higher Tumor Absorbed Dose (TAD) than [225Ac]Ac-DOTA-TATE. This is attributed to the superior tumor uptake and prolonged retention of the antagonist.

D. Cellular Retention Mechanism

• Real-time binding assays showed that [225Ac]Ac-SSO110 maintained a sustained cell-associated $\beta^-$ signal even after washing, whereas the $^{177}$Lu-labeled version showed measurable dissociation.
• This suggests that while the antagonist does not internalize, the daughter radionuclides (or the decay chain products) remain effectively trapped at the cell surface or within the immediate tumor microenvironment, likely due to short recoil ranges and limited diffusion.

5. Significance and Conclusion

• Paradigm Shift: The study concludes that receptor-mediated internalization is not required for the effective retention of $^{225}$Ac daughter radionuclides in rapidly clearing peptide-based therapies.
• Therapeutic Advantage: The SSTR2 antagonist [225Ac]Ac-SSO110 offers a superior therapeutic profile compared to the agonist [225Ac]Ac-DOTA-TATE, providing significantly higher tumor doses and better tumor-to-kidney ratios without increasing the risk of daughter redistribution toxicity.
• Clinical Implication: These findings support the clinical development of antagonist-based $^{225}$Ac radioligand therapies, suggesting that ligand pharmacokinetics and receptor affinity are more critical determinants of daughter retention than internalization kinetics. This opens new avenues for treating tumors with heterogeneous receptor expression where agonists may fail.